Research Unit Analytical Pathology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Leipzig, Germany.
Clin Cancer Res. 2022 Jul 1;28(13):2865-2877. doi: 10.1158/1078-0432.CCR-21-4383.
Current systems of gastric cancer molecular classification include genomic, molecular, and morphological features. Gastric cancer classification based on tissue metabolomics remains lacking. This study aimed to define metabolically distinct gastric cancer subtypes and identify their clinicopathological and molecular characteristics.
Spatial metabolomics by high mass resolution imaging mass spectrometry was performed in 362 patients with gastric cancer. K-means clustering was used to define tumor and stroma-related subtypes based on tissue metabolites. The identified subtypes were linked with clinicopathological characteristics, molecular features, and metabolic signatures. Responses to trastuzumab treatment were investigated across the subtypes by introducing an independent patient cohort with HER2-positive gastric cancer from a multicenter observational study.
Three tumor- and three stroma-specific subtypes with distinct tissue metabolite patterns were identified. Tumor-specific subtype T1(HER2+MIB+CD3+) positively correlated with HER2, MIB1, DEFA-1, CD3, CD8, FOXP3, but negatively correlated with MMR. Tumor-specific subtype T2(HER2-MIB-CD3-) negatively correlated with HER2, MIB1, CD3, FOXP3, but positively correlated with MMR. Tumor-specific subtype T3(pEGFR+) positively correlated with pEGFR. Patients with tumor subtype T1(HER2+MIB+CD3+) had elevated nucleotide levels, enhanced DNA metabolism, and a better prognosis than T2(HER2-MIB-CD3-) and T3(pEGFR+). An independent validation cohort confirmed that the T1 subtype benefited from trastuzumab therapy. Stroma-specific subtypes had no association with clinicopathological characteristics, however, linked to distinct metabolic pathways and molecular features.
Patient subtypes derived by tissue-based spatial metabolomics are a valuable addition to existing gastric cancer molecular classification systems. Metabolic differences between the subtypes and their associations with molecular features could provide a valuable tool to aid in selecting specific treatment approaches.
目前的胃癌分子分类系统包括基因组、分子和形态学特征。基于组织代谢组学的胃癌分类仍然缺乏。本研究旨在定义代谢上不同的胃癌亚型,并确定其临床病理和分子特征。
对 362 例胃癌患者进行高分辨率成像质谱的空间代谢组学分析。基于组织代谢物,采用 K-均值聚类法定义肿瘤和基质相关亚型。将鉴定出的亚型与临床病理特征、分子特征和代谢特征联系起来。通过引入来自多中心观察性研究的 HER2 阳性胃癌患者的独立患者队列,研究了各亚型对曲妥珠单抗治疗的反应。
鉴定出三种具有不同组织代谢模式的肿瘤和三种基质特异性亚型。肿瘤特异性亚型 T1(HER2+MIB+CD3+)与 HER2、MIB1、DEFA-1、CD3、CD8、FOXP3 呈正相关,与 MMR 呈负相关。肿瘤特异性亚型 T2(HER2-MIB-CD3-)与 HER2、MIB1、CD3、FOXP3 呈负相关,与 MMR 呈正相关。肿瘤特异性亚型 T3(pEGFR+)与 pEGFR 呈正相关。与 T2(HER2-MIB-CD3-)和 T3(pEGFR+)相比,T1(HER2+MIB+CD3+)患者的核苷酸水平升高,DNA 代谢增强,预后较好。独立验证队列证实 T1 亚型受益于曲妥珠单抗治疗。基质特异性亚型与临床病理特征无关,但与独特的代谢途径和分子特征相关。
基于组织的空间代谢组学衍生的患者亚型是现有胃癌分子分类系统的有益补充。亚型之间的代谢差异及其与分子特征的关联可能为选择特定治疗方法提供有价值的工具。